History of immunoglobulin replacement.
The provision of antibodies to prevent and treat infection began with the application of "curative serum" in the first years of the last century. After the process of large-scale plasma fractionation was developed in the 1940s, the general use of immunoglobulin expanded. Intravenous immunoglobulin products became available in the 1970s, and their only use for the provision of antibodies governed the opinion of experts over the next decade. Modulation of inflammation and immunosuppression were introduced in treatment of inflammatory and autoimmune diseases and became accepted indications. The history of adverse events of treatment and their management are outlined in this article. Consensus indications and evidence-based off-label uses are discussed.
Eibl
Martha M
MM
Medical University of Vienna, Center for Physiology, Pathophysiology and Immunology, Institute of Immunology, Borschkegasse 8a, 1090 Vienna, Austria. martha.eibl@meduniwien.ac.at
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015975:Consensus Development Conferences, NIH as Topic; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007116:Immunization, Passive / Q000266:history*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects* / Q000737:chemistry / Q000276:immunology; D007153:Immunologic Deficiency Syndromes / Q000266:history / Q000628:therapy*; D009316:National Institutes of Health (U.S.) / Q000266:history; D014481:United States
D000911:Antibodies, Monoclonal; D016756:Immunoglobulins, Intravenous